29 search results for: tim-blackstock

Decision Resources Group’s analysts looked back at the key cardiovascular, metabolic, renal, and hematological market events that shaped 2018. Below...

Understanding Patient Demographics, Treatment Pathways, and Physician Prescribing Behavior How is Chronic Heart Failure Treated Today? Chronic heart...

Insights on the Gut Microbiome, Obesity, and NAFLD: Part I   The human gastrointestinal (GI) tract is home to trillions of microorganisms, often...

The PROs and CONS of Prescription Weight Loss Medications World Obesity Day is on October 11, and it is a timely reminder of the obesity epidemic...

I must admit it, I am surprised by the scale of the risk reduction that Amarin Corporation’s Vascepa (icosapent ethyl) has delivered in the REDUCE-...

Esperion Therapeutics’ lead candidate, bempedoic acid, a novel cholesterol-lowering agent, has made steady progress and could meet an important...

Currently, only liver biopsy can provide a definitive diagnosis of NASH. As such, it is required for clinical trials evaluating novel therapies and...

Overall, 2017 was not exactly a stellar year for the obesity drug market, with more downs than ups, and although the unmet need for novel drug...

Non-alcoholic steatohepatitis (NASH) is fast becoming a highly competitive drug development race; the high prevalence of the disease, the substantial...

Some substance was added to all the hype around non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) in 2017. New drug...

Although 2017 was not awash with exciting novel therapies or practice-changing research, the importance of managing lipid levels to reduce the risk of...

DRG cardiovascular, metabolic, renal, and hematologic (CMRH) disease experts have compiled their top ten market events in 2017. Events run the gamut...

The statin class provided a major breakthrough for managing high cholesterol, a key modifiable risk factor for cardiovascular (CV) disease, and are...

ACC is done for another year, with a multitude of exciting trials presented, including FOURIER, EBBINGHAUS, SPIRE-1 and -2, ORION-1, and CARAT. There...

A lot of the hype surrounding ACC.17 is due to the release of cardiovascular (CV) outcomes data for Repatha (evolocumab), Amgen’s PCSK9 inhibitor...

We are potentially on the brink of another massive leap forward in terms of cardiovascular (CV) disease prevention. The first of the late-breaking...

Earlier this month saw President Trump call for an overhaul of the FDA and the way it approves drugs, in particular accelerating the drug approval...

High-fat diets are all the rage these days, and ACC.17 has some serious high-fat content on the menu for dyslipidemia devotees. Some of the fare...

Have you ever had that holiday experience, when you thought you were going to receive an amazing gift, but when the big day arrived you got socks?...

Christmas is a time of giving, and non-alcoholic steatohepatitis (NASH) is one disease that keeps on giving. Not only is it highly prevalent and...